BELLUS Health is a clinical-stage biopharmaceutical company. Co.'s primary drug candidate is BLU-5937, being developed for the treatment of chronic cough. In preclinical studies, BLU-5937 exhibited an anti-tussive effect without affecting taste perception and a safety profile. BLU-5937 has the potential to be therapeutic for chronic cough patients who do not respond to existing therapies. The Phase 1 data demonstrated that BLU-5937 has a tolerability profile, as well as a pharmacokinetic profile supporting twice-a-day dosing. Co. has obtained from NEOMED Institute an exclusive worldwide license to develop and commercialize BLU-5937. The BLU stock yearly return is shown above.
The yearly return on the BLU stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BLU annual return calculation with any dividends reinvested as applicable (on ex-dates).
|